If the return to market does in fact take place, you could very well be looking at an immediate $5.00 to $10.00+ pop in share price (or more), partially depending on whether or not the Fresenius dialysis centers will distribute the drug to patients. If not, then other avenues will need to be negotiated to get the drug to patients. Until that time, investors may continue to experience wild swings on news, distorted news, or a complete lack of news.
Takeda is taking direct aim at Amgen's ongoing anemia drug monopoly and OMONTYS was expected to play a major role in that initiative. Takeda has deep pockets and a keen reputation for not giving up too easily.